Akebia Therapeutics (AKBA) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Entrada Therapeutics (TRDA) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 10.2% versus a loss of 71.4%. Akebia Therapeutics is the larger company by market cap ($225.8 million vs $215.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | TRDA |
|---|---|---|
| Share price | $0.8148 | $5.53 |
| Market cap | $225.79M | $215.32M |
| 1-day change | -6.71% | -1.43% |
| YTD return | -49.39% | -46.21% |
| 1-year return | -71.41% | -10.23% |
| 5-year return | -71.41% | — |
| EPS (TTM) | $-0.12 | $-3.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $16.45 |
| 52-week low | $0.814 | $5.15 |
| Distance from 52-week high | -74.54% | -66.38% |
| Analyst consensus | none | none |
| Avg. price target upside | +381.10% | +243.58% |
| Average volume | 6.18M | 359.01K |
| Shares outstanding | 277.11M | 38.94M |
| Employees | 194 | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRDA has outperformed AKBA by 61.2 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
AKBA vs TRDA FAQ
Which is bigger, Akebia Therapeutics or Entrada Therapeutics?
Akebia Therapeutics (AKBA) is larger, with a market capitalization of $225.79M compared with $215.32M for Entrada Therapeutics (TRDA).
Which stock has performed better over the past year, AKBA or TRDA?
TRDA returned -10.23% over the past 12 months, compared with -71.41% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.